Clinical trials: Non-small Lung Cancer
Advanced Nonhaematologic Malignancies
Safety, Efficacy, and Tolerability of BOS172738 in Patients With Advanced Rearranged During Transfection (RET) Gene-Altered Tumors
This study will be conducted to assess the safety and tolerability of BOS172738 when administered to patients with advanced solid tumors with rearranged during transfection (RET) gene alterations and also to establish the maximum…
- Trial name
- NCT03780517
- Testing
- BOS172738
- Where
- 21 sites in United States, Belgium and 5 more
- Volunteers
- 117 people
- Sponsor
- Boston Pharmaceuticals
Lung Cancer
A Study to Learn About Dacomitinib in Patients With Non-small Cell Lung Cancer.
The purpose of this study is to learn about dacomitinib for the possible treatment of lung cancer. This study is seeking participants who: have lung cancer that could not be controlled.
- Trial name
- NCT06321510
- Where
- Taiwan
- Volunteers
- 29 people
- Sponsor
- Pfizer
Non Small Cell Lung Cancer, Brain Metastases
Cadonilimab Combined With Stereotactic Radiotherapy as Second-line Treatment for Brain Metastases
The goal of this clinical trial is to evaluate the efficacy and safety of Cadonilimab combined with stereotactic radiation therapy in the second-line treatment of brain metastases from non-small cell lung cancer (NSCLC).
- Conditions
- Non Small Cell Lung Cancer, Brain Metastases, Stereotactic Radiation, Immunotherapy
- Trial name
- NCT06702826
- Testing
- Cadonilimab combined with SRS
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Rongrong Zhou
Carcinoma, Non-small Cell Lung Cancer
Circulating Tumor DNA Longitudinal Monitoring in Stage III-IV Lung Cancer Patients
Conduct a prospective study in multicenter to confirm the value of circulating tumor DNA in longitudinal monitoring of stage III-IV lung cancer patients.
- Conditions
- Carcinoma, Non-small Cell Lung Cancer, Lung Neoplasm
- Trial name
- NCT03664843
- Where
- 8 sites in China
- Volunteers
- 120 people
- Sponsor
- First Hospital of Shijiazhuang City
Lung Cancer
The Lived Experiences of Persons With Early Stage Non-small Cell Lung Cancer and Their Significant Other(s) Following Surgery: a Rapid Ethnographic Approach
To understand the lived experiences, thoughts and habits about exercise and PA of persons with early stage non-small cell lung cancer and their significant other(s) following surgery.
- Trial name
- LEILA (NCT06536140)
- Testing
- Home observations and interview
- Where
- Belgium
- Volunteers
- 16 people
- Sponsor
- Hasselt University
Lung Cancer
Combination Chemotherapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00005825
- Testing
- cisplatin, mitomycin C, tretinoin
- Where
- United States
- Sponsor
- Raghu Nandan, M.D., Inc
Non-small Cell Lung Cancer
Study of BMS-275183 in Patients With Pretreated Locally Advanced or Metastatic NSCLC (Non Small Cell Lung Cancer)
BMS-275183 given orally twice weekly to patients pretreated for locally advanced or metastatic NSCLC will show anti-tumor activity in any of the 3 separate cohorts of the patients enrolled: Cohort I: Patients previously treated…
- Trial name
- NCT00359450
- Testing
- BMS-275183 (oral taxane)
- Where
- 30 sites in United States, Belgium and 6 more
- Volunteers
- 186 people
- Sponsor
- Bristol-Myers Squibb
Lung Cancer, TKI Resistance
A Single Center, Single Arm Clinical Study on the Treatment of Advanced Non-small Cell Lung Cancer With Positive EGFR Sensitive Mutations and Failed EGFR TKIs With the Combination of Enrotinib and Paclitaxel Monoclonal Antibody
Lung cancer is the second most common malignancy and mortality rate in the world. In the United States and Europe, approximately 10% to 15% of NSCLC patients have epidermal growth factor receptor (EGFR)-sensitive mutations, with…
- Conditions
- Lung Cancer, TKI Resistance, EGFR Sensitive Mutation, Anlotinib
- Trial name
- NCT06048315
- Testing
- Anlotinib, Penpulimab
- Volunteers
- 52 people
- Sponsor
- Degan Lu
Lung Cancer
Ph II Adjuvant Carboplatin/Docetaxel in Curatively Resected Stage I-IIIA NSCLC
RATIONALE: Drugs used in chemotherapy, such as carboplatin and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00280735
- Testing
- carboplatin, docetaxel
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Non-small Cell Lung Cancer
MRD-guided Prognosis Prediction and Adjuvant Treatment Based on CTC and ctDNA in NSCLC
This is a prospective cohort study, which aims to evaluate the effectiveness and superiority of a novel minimal residual disease-guided prognosis monitoring and adjuvant treatment in stage IIA-IIIC non-small cell lung cancer.
- Trial name
- NCT06198868
- Testing
- Operable
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Jiangsu Cancer Institute & Hospital
Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer
CCI-779 in Treating Patients With Stage IIIB (With Pleural Effusion) or Stage IV Non-Small Cell Lung Cancer
This phase II trial is studying how well CCI-779 works in treating patients with stage IIIB non small cell lung cancer (with pleural effusion) or stage IV non-small cell lung cancer.
- Conditions
- Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
- Trial name
- NCT00079235
- Testing
- temsirolimus, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- National Cancer Institute (NCI)
Lung Cancer
R115777 in Treating Patients With Recurrent or Metastatic Non-small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of R115777 in treating patients who have recurrent or…
- Trial name
- NCT00005989
- Testing
- tipifarnib
- Where
- 3 sites in United States
- Sponsor
- Mayo Clinic
ALK Gene Rearrangement Positive, Non-Squamous Non-Small Cell Neoplasm of Lung
Alectinib in Combination With Bevacizumab in ALK Positive NSCLC
This single-arm, open-label, phase II clinical study aims to evaluate the progression-Free Survival (PFS) of the combination of Alectinib plus Bevacizumab in untreated and first and second-line chemotherapy failed subjects with…
- Trial name
- NCT03779191
- Testing
- Alectinib, Bevacizumab
- Where
- Mexico
- Volunteers
- 41 people
- Sponsor
- Instituto Nacional de Cancerologia de Mexico
Robotics, Lung Cancer
SP Robotic Versus VATS Anatomical Pulmonary Resection for Patients With NSCLC
Single-POrt Robotic-assisted thoracic surgery versus single-port video-assisted Thoracic Surgery major pulmonary resection for patients with non-small cell lung cancer (SPORTS trial): a single-center, a single blinded, randomized…
- Trial name
- SPORTS (NCT06202690)
- Testing
- Single-port robotic-assisted thoracic surgery, Single-port video-assisted thoracoscopic surgery
- Volunteers
- 290 people, healthy volunteers welcome
- Sponsor
- Korea University Guro Hospital
Metastatic Non-small Cell Lung Cancers
Amivantamab, Lazertinib, and Pemetrexed for First-line Treatment of Recurrent/Metastatic Non-small Cell Lung Cancers With Epidermal Growth Factor Receptor Mutations
This is a phase II, single-arm, multicenter trial, conducted through Latin American Coorperative Oncology Group (LACOG). Treatment-naïve patients with recurrent/metastatic NSCLCs harboring EGFR exon 19 deletions or exon 21 L858R…
- Trial name
- AMIGO-1 (NCT05299125)
- Testing
- Amivantamab, Lazertinib, Pemetrexed 500 mg
- Where
- 13 sites in Brazil
- Volunteers
- 54 people
- Sponsor
- Latin American Cooperative Oncology Group
Lung Neoplasm
Brazilian Lung Immunotherapy Study
Immunotherapy with anti-PD-1/PD-L1 agents either as single agents or combined with chemotherapy is now considered the standard of care for patients with non-small-cell lung cancer.
- Trial name
- BLISS (NCT05081674)
- Testing
- Alectinib, Pembrolizumab, Nivolumab
- Where
- Brazil
- Volunteers
- 154 people
- Sponsor
- Hospital Israelita Albert Einstein
Non-Small Cell Lung Cancer
A Study of Tarceva (Erlotinib) in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Following 4 Cycles of Platinum-based Chemotherapy Without Disease Progression
This open-label, single-arm study will evaluate the safety and efficacy of Tarceva (erlotinib) in patients with locally advanced or metastatic non-small cell lung cancer who have completed 4 cycles of standard platinum-based…
- Trial name
- NCT01230710
- Testing
- Erlotinib
- Where
- 7 sites in India
- Volunteers
- 51 people
- Sponsor
- Hoffmann-La Roche
Non-Small Cell Lung Cancer
Study of Erlotinib With Docetaxel in Selected Non Small Cell Lung Cancer Patients in First Line Treatment
Study Rationale: There is increasing evidence that erlotinib improves overall survival in selected patients with stage IIIB-IV NSCLC.
- Trial name
- NCT00840125
- Testing
- erlotinib, docetaxel
- Where
- Israel
- Volunteers
- 4 people
- Sponsor
- Meir Medical Center
Lung Cancer Non Small Cell
Comprehensive Demographics and Clinical Profile of NSCLC Patients
Advances in the treatment of non-small cell lung cancer in the last decade have been significant. Currently, there are several first-line therapeutic options.
- Trial name
- CA209-1529 (NCT06725537)
- Volunteers
- 500 people
- Sponsor
- D'Or Institute for Research and Education
Colorectal Cancer
Lapatinib Plus Trametinib in KRAS Mutant NSCLC
This is an open-label phase I/II multi-center study consisting of two parts. Part A of this study is designed to identify the recommended phase 2 dose (RP2D) of lapatinib combined with trametinib in patients with metastatic KRASm…
- Trial name
- M14LTK (NCT02230553)
- Testing
- Lapatinib, trametinib
- Where
- Netherlands
- Volunteers
- 35 people
- Sponsor
- The Netherlands Cancer Institute
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.